Thiazolidinediones × glycemic control

TrialThe Journal of clinical endocrinology and metabolism2005

Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin.

Antti P M Viljanen et al.PubMed ↗Publisher ↗

What the trial testedas reported · 2005

No range given

Reported higher glycemic control, no range given

+72.0percentage points

As reported

difference 72 %, no interval

No range given

Reported lower glycemic control, no range given

−18.0percentage points

As reported

difference −18.0 %, no interval

+1 more in the walkthrough ↓

Three numbers in the abstract

the abstract, start to end

Rosiglitazone treatment increased flow by 72% (P < 0.01) and GU by 23% (P < 0.05) and thereby decreased adipose tissue glucose extraction by 18% (P < 0.05); no changes were

treatment increased flow by 73% (P < 0.01) and GU by 24% (P <

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Glycemic control
72
Glycemic control
−18.0
Body weight & composition
73
ThiazolidinedionesGlycemic controlBody weight & composition
1 / 4

9 papers cite it

2005
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 16189256